DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, and provider of contract services to the diagnostics, life sciences and pharmaceutical industries, today announced the expansion of its Contract Services business and the launch of its dedicated Contract Services website, www.corgenix.net. The new site complements the existing www.corgenix.com site and reflects the company’s strong growth and dedicated strategic approach to its Contract Services business unit for diagnostic products.
“Contract Services, including contract manufacturing, contract development, companion diagnostics and partner support activities, has become an increasingly important part of our business, and as a result we are significantly expanding our capabilities,” said Corgenix President and Chief Executive Officer Douglass Simpson. “Our company is already an established industry leader for in vitro diagnostics development and manufacturing. As the demand for companion diagnostics grows, Corgenix is adding new resources to assist pharmaceutical and biotechnology companies with the development of these promising tests, which aid in stratifying patient populations and determining the effectiveness of specific corresponding therapies.”
The company’s Contract Services business is supported by a dedicated team of highly qualified and experienced scientific researchers, laboratory and operations professionals. Corgenix’ facilities function as a full-service operation to support and partner with its customers on everything from product concept to product distribution.
In addition to contract manufacturing services, the company’s portfolio of outsourced services includes:
- Product development
- Technology application
- Private labeling
- Regulatory management
- Warehousing and fulfillment
- Distribution and commercialization
For more than twenty years, Corgenix has provided Contract Services to large and small medical companies, pharmaceutical and biotechnology companies, universities, research institutions and government agencies. The company’s expertise, quality system, solid infrastructure and state-of-the-art manufacturing facility have attracted partners from across the globe.
For more information on Corgenix’ Contract Services, visit the company’s new website at www.corgenix.net.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com.
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements, which are inherently uncertain, are based on management’s current expectations and are subject to various factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission, and in the Company’s subsequent filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation or intend to publicly update or revise any forward-looking statements.
